ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Macrophage"

  • Abstract Number: 3003 • 2014 ACR/ARHP Annual Meeting

    Am80 Ameliorates Bleomycin-Induced Dermal Fibrosis By Suppressing the Pro-Fibrotic Phenotype of Fibroblasts, Endothelial Cells, and Immune Cells

    Tetsuo Toyama1, Yoshihide Asano1, Takehiro Takahashi1, Ryosuke Saigusa1, Yohei Ichimura1, Takashi Taniguchi1, Shinji Noda1, Kaname Akamata1, Shinichi Sato1, Takafumi Kadono1 and Koichi Shudo2, 1Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2Reseach Foundation ITSUU Laboratory, Tokyo, Japan

    Background/Purpose:  Am80 is a synthetic retinoid serving as an agonist for retinoic acid receptor α/β with chemical and pharmacological advantages over all-trans retinoic acid, such…
  • Abstract Number: 2952 • 2014 ACR/ARHP Annual Meeting

    S100A9 Inhibitor Paquinimod (ABR-215757) reduces Joint Destruction in Experimental Osteoarthritis and Blocks Activating Effects of S100A9 in OA Synovium

    Peter L. van Lent1, Rik Schelbergen2, Arjen B. Blom1, Tomas Leanderson3, Helena Eriksson4 and Wim B. van den Berg5, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2Radboud university medical center, Nijmegen, Netherlands, 3Immunology Group, Lund University, Lund, Sweden, 4BioScience, Active Biotech AB, Lund, Sweden, 5Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose Synovial activation is present in more than 50% of osteoarthritis (OA) patients and it is thought to be involved in the development of OA…
  • Abstract Number: 2127 • 2014 ACR/ARHP Annual Meeting

    Subclinical Arthritis Is Detected By Macrophage Targeting and Positron Emission Tomography (PET) in Early RA Patients in Clinical Remission

    Y.Y.J. Gent1, M.M. ter Wee1, D den Uyl1, N. Ahmadi2, W.F. Lems3, O.S. Hoekstra4, A.E. Voskuyl1 and C.J. Van der Laken3, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Radiology, VU University Medical Center, Amsterdam, Netherlands, 3Rheumatology, VU Medical Center, Amsterdam, Netherlands, 4Nuclear Medicine, VU Medical Center, Amsterdam, Netherlands

    Background/Purpose: Recurrent flares in RA patients in complete remission (CR) are not an uncommon phenomenon. Studies with advanced imaging techniques have suggested that residual subclinical…
  • Abstract Number: 1714 • 2014 ACR/ARHP Annual Meeting

    IL-6 Trans-Signalling Activates M2 Macrophage Polarisation and Mediates Fibrotic Response in Scleroderma

    Rebecca Alade, Shiwen Xu, Korsa Khan, Angela Tam, Christopher P. Denton and Voon H. Ong, Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom

    Background/Purpose IL6 is a key mediator in activation of extracellular matrix (ECM) in scleroderma (SSc) fibroblasts and via its interplay with chemokines may modulate mononuclear…
  • Abstract Number: 1651 • 2014 ACR/ARHP Annual Meeting

    Association of Glomerular Macrophage Phenotypes and Urine Soluble CD163 with Disease Activity in Human Lupus Nephritis

    Naotake Tsuboi1, Nobuhide Endo1, Seiichi Matsuo2 and Shoichi Maruyama1, 1Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose: In addition to the effector roles of classically activated macrophages for tissue injury, recent studies have shown that alternatively activated (M2) macrophages are involved…
  • Abstract Number: 1486 • 2014 ACR/ARHP Annual Meeting

    Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá

    Iain B. McInnes1, Gerd Burmester2, Joel M. Kremer3, Pedro Miranda4, Mariusz Korkosz5, Jiri Vencovsky6, Andrea Rubbert-Roth7, Eduardo Mysler8, David Close9, Matthew A. Sleeman10, Alex Godwood11, Sara Sandbach12, Patricia C. Ryan13, Dominic Sinibaldi14, Wendy White13, Nadine A. Defranoux15 and Michael Weinblatt16, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, 3Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 4Centro de Estudios Reumatologicos, Santiago, Chile, 5Inernal Medicine and Gerontology, Malopolskie Centrum Medyczne, Krakow, Poland, 6Rheumatology, Charles University Institute of Rheumatology, Prague, Czech Republic, 7Med Clinic I, University of Cologne, koln, Germany, 8Rheumatology, OMI, Buenos Aires, Argentina, 9Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, 10Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, 11Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, 12Clinical biologics, MedImmune Ltd, Cambridge, United Kingdom, 13Translational Sciences, MedImmune, Gaithersburg, MD, 14R&D IS Translational & Clinical Informatics, MedImmune, Gaithersburg, MD, 15Crescendo Bioscience Inc., South San Francisco, CA, 16Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose Macrophages are pivotal to rheumatoid pathogenesis and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophage activation and…
  • Abstract Number: 1493 • 2014 ACR/ARHP Annual Meeting

    A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results

    Julie Hambleton1, Lei Zhou1, Seema Rogers1, Sjoerd van Marle2, Thijs van Iersel2, James Zanghi1, Emma Masteller1, Kevin Baker1 and Brian Wong1, 1Five Prime Therapeutics, South San Francisco, CA, 2PRA Health Sciences, Groningen, Netherlands

    Background/Purpose Activation of CSF1R via IL34 or CSF1 results in activation, differentiation, and survival of monocytes, macrophages and osteoclasts.  CSF1R activation produces inflammatory cytokines responsible…
  • Abstract Number: 1764 • 2013 ACR/ARHP Annual Meeting

    Binding Of Apoptotic Fetal Cardiocytes By Anti-Ro Antibodies Stimulates uPA/uPAR- Dependent Macrophage Infiltration and M2 Type Phenotype

    Paraskevi Briasouli1, Savvas Pavlides2, Leslie Gold3, Mark Halushka4 and Jill P. Buyon5, 1Rheumatology, New York University Medical Center, New York, NY, 2New York University Medical Center, new York, NY, 3new York University Medical Center, new York, NY, 4Division of Cardiovascular Pathology, John Hopkins Pathology, Baltimore, MD, 5Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY

    Background/Purpose: Organ injury induced by antibodies characteristic of Sjogren's Syndrome and Systemic Lupus Erythematosus, while varied in the adult and fetus, may share in common…
  • Abstract Number: 1730 • 2013 ACR/ARHP Annual Meeting

    Novel Role For Ly6C– Monocyte Subsets and Joint Macrophages In Mouse Model Of Rheumatoid Arthritis

    Alexander Misharin1, Carla M. Cuda2, Rana Saber3, Angelica K. Gierut4, G. Kenneth Haines III5, Steffen Jung6 and Harris R. Perlman7, 1Medicine, Division of Rheumatology, Northwestern University, Chicago, IL, 2Medicine / Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Medicine/Rheumatology, Northwestern University, Chicago, IL, 4Rheumatology, Northwestern Med Faculty Found, Chicago, IL, 5Department of Pathology, Yale University, New Haven, CT, 6Immunology, Weizmann Institute, Rehovot, Israel, 7Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Monocytes and macrophages play a key role in the pathogenesis of rheumatoid arthritis. However, role of the individual subsets of monocytes and macrophages in…
  • Abstract Number: 1279 • 2013 ACR/ARHP Annual Meeting

    Anti-IL-6 Receptor Antibody Is Effective In Arthritis Regardless Of Obesity In Mouse Model

    Miho Suzuki, Hiroto Yoshida and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan

    Background/Purpose: Compared with non-obese patients, obese patients with rheumatoid arthritis (RA) reportedly experience worsening of symptoms [Arthritis Care Res (Hoboken). 2013; 65: 78-87] and do…
  • Abstract Number: 1159 • 2013 ACR/ARHP Annual Meeting

    Exercise Suppresses Systemic Inflammation Via Inhibition Of NF-κB Activation In Monocytes

    Alisa Blazek1, Derrick Knapik2, Lai-Chu Wu3, Nicholas A. Young3, Wael N. Jarjour4 and Sudha Agarwal5, 1Molecular, Cellular and Developmental Biology, The Ohio State University, Columbus, OH, 2College of Medicine, The Ohio State University, Columbus, OH, 3Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 4Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, 5Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH

    Background/Purpose: Inflammation is integral to joint damage and bone erosion in rheumatoid arthritis.  We reported previously that physiologic levels of exercise are anti-inflammatory and suppress local…
  • Abstract Number: 1150 • 2013 ACR/ARHP Annual Meeting

    Differential Regulation Of IL-10 and Dusp1 Production By Kinases In The p38 MAPK Pathway

    Deepa Hammaker1, Katharyn Topolewski2 and G. S. Firestein3, 1MC 0656, UCSD School of Medicine, La Jolla, CA, 2UCSD School of Medicine, La Jolla, CA, 3Div of Rheumatology, UCSD School of Medicine, La Jolla, CA

    Background/Purpose: MAPK kinases MKK3 and MKK6 regulate p38 function in inflammatory diseases like rheumatoid arthritis (RA). Targeting MKK3 or MKK6 might be superior to traditional…
  • Abstract Number: 933 • 2013 ACR/ARHP Annual Meeting

    Characterizing The Expression and Function Of CCL28 and Its Corresponding Receptor CCR10 In The Pathogenesis Of RA

    Zhenlong Chen1, Seung-jae Kim1, Michael V. Volin2, Suncica Volkov1, William Swedler3, Nadera J. Sweiss4 and Shiva Shahrara1, 1Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, 2Department of Microbiology and Immunology, Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL, 3Section of Rheumatology, University of Illinois at Chicago, Chicago, IL, 4internal medicine section of rheumatology, University of Illinois at Chicago, Chicago, IL

    Background/Purpose: This study was conducted to determine the expression pattern and function of CCL28 and its corresponding receptor CCR10 in the pathogenesis of rheumatoid arthritis…
  • Abstract Number: 823 • 2013 ACR/ARHP Annual Meeting

    Activation Of Liver X Receptors Inhibits Experimental Fibrosis By Interfering With Interleukin-6 Release From Macrophages

    Christian Beyer1, Jürgen Beer1, Katrin Palumbo-Zerr1, Pawel Zerr1, Alfiya Distler1, Clara Dees1, Louis E. Munoz1, Gerhard Krönke1, Oliver Distler2, Steve Anderson3, Georg A. Schett4 and Joerg H. W. Distler1, 1Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 3Lexicon Pharmaceuticals Inc., The Woodlands, TX, 4Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Liver X receptors (LXRs) are orphan nuclear receptors with emerging roles in metabolic and autoimmune diseases. Here, we investigated the role of LXRs in…
  • Abstract Number: 766 • 2013 ACR/ARHP Annual Meeting

    Cholesterol Accumulation By Synovial Lining Macrophages Results In Ectopic Bone Formation During Experimental Osteoarthritis

    Wouter de Munter1, Arjen B. Blom1, Monique M. Helsen1, Birgitte Walgreen1, Peter M. van Der Kraan1, Leo A. Joosten2, Wim B. van den Berg3 and Peter L. van Lent4, 1Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, 3Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands, 4Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Synovial macrophages have previously shown to play a significant role in the etiopathology of experimental collagenase-induced osteoarthritis (OA). In addition to production of pro-inflammatory…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology